Jeffcoat M K, Williams R C, Kaplan M L, Goldhaber P
J Periodontol. 1985 Nov;56 Suppl 11S:8-12. doi: 10.1902/jop.1985.56.11s.8.
Nuclear medicine was used to assess the activity of alveolar bone loss in beagle dogs treated with the nonsteroidal anti-inflammatory drug flurbiprofen. Radiographic measurements of the rate of bone loss were taken during a 6-month "pretreatment" period and a 9month treatment period. During the treatment period six dogs received a placebo, and six dogs received orally 0.02 mg/kg flurbiprofen daily for 9 months. In addition, each dog received periodontal surgery in one half of the mouth at the end of the pretreatment period. The rate of alveolar bone loss was significantly decreased in the treatment period in the flurbiprofen-treated dogs (P < 0.001). Measurements of boneseeking radiopharmaceutical uptake were taken 3 months after the initiation of therapy. The single measurement of uptake was compared to the rate of bone loss determined from repeated radiographs taken during the 9-month treatment period. Bone-seeking radiopharmaceutical uptake was an accurate indicator of "active" bone loss in 83.5% of the teeth studied.
核医学被用于评估用非甾体抗炎药氟比洛芬治疗的比格犬牙槽骨丧失的活性。在为期6个月的“预处理”期和9个月的治疗期内，对骨丧失率进行了影像学测量。在治疗期，6只犬接受安慰剂，6只犬每天口服0.02 mg/kg氟比洛芬，持续9个月。此外，在预处理期结束时，每只犬在半侧口腔接受了牙周手术。在治疗期，氟比洛芬治疗的犬牙槽骨丧失率显著降低（P<0.001）。在治疗开始3个月后，对骨摄取放射性药物的情况进行了测量。将单次摄取测量结果与在9个月治疗期内通过重复X光片确定的骨丧失率进行比较。在所研究的牙齿中，骨摄取放射性药物是83.5%的“活动性”骨丧失的准确指标。
